This HTML5 document contains 58 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n13http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00064173%3A_____%2F10%3A00002699%21RIV13-MZ0-00064173/
dctermshttp://purl.org/dc/terms/
n8http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n5http://linked.opendata.cz/resource/domain/vavai/projekt/
n17http://linked.opendata.cz/ontology/domain/vavai/
n7http://linked.opendata.cz/resource/domain/vavai/zamer/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n19http://bibframe.org/vocab/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n4http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n6http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n16http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n10http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n18http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n12http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n15http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00064173%3A_____%2F10%3A00002699%21RIV13-MZ0-00064173
rdf:type
n17:Vysledek skos:Concept
dcterms:description
1. Hypertension plays a critical role in the progression of chronic kidney disease (CKD) to end-stage renal disease (ESRD), but it has also been postulated that antihypertensive drugs that block the renin-angiotensin system (RAS) show class-specific renoprotective actions beyond their blood pressure (BP)-lowering effects. 2. Because this notion has recently been questioned, in the present study we compared the effects of a RAS-dependent antihypertensive therapy (a combination of trandolapril, an angiotensin-converting enzyme inhibitor (ACEI) and losartan, an angiotensin-II (AngII) receptor subtype 1A receptor antagonist) with a %22RAS-independent%22 antihypertensive therapy (a combination of labetalol, an alfa- and beta-adrenoreceptor antagonist with the diuretics, hydrochlorothiazide and furosemide) on the progression of CKD after 5/6 renal ablation (5/6 NX) in Ren-2 renin transgenic rats (TGR), a model of AngII-dependent hypertension. Normotensive transgene-negative Hannover Sprague-Dawley (HanSD) rats after 5/6 NX served as controls. 3. RAS-dependent and -independent antihypertensive therapies normalized BP and survival rate, and prevented the development of cardiac hypertrophy and glomerulosclerosis to the same degree in 5/6 NX HanSD rats and in 5/6 NX TGR. The present findings show that renoprotection, at least in rats after 5/6 NX, is predominantly BP-dependent. When equal lowering of BP was achieved, leading to normotension, cardio- and renoprotective effects were equivalent irrespective of the type of antihypertensive therapy. 4. These findings should be taken into consideration in attempts to develop new therapeutic approaches and strategies aimed to prevent the progression of CKD and to lower the incidence of ESRD. 1. Hypertension plays a critical role in the progression of chronic kidney disease (CKD) to end-stage renal disease (ESRD), but it has also been postulated that antihypertensive drugs that block the renin-angiotensin system (RAS) show class-specific renoprotective actions beyond their blood pressure (BP)-lowering effects. 2. Because this notion has recently been questioned, in the present study we compared the effects of a RAS-dependent antihypertensive therapy (a combination of trandolapril, an angiotensin-converting enzyme inhibitor (ACEI) and losartan, an angiotensin-II (AngII) receptor subtype 1A receptor antagonist) with a %22RAS-independent%22 antihypertensive therapy (a combination of labetalol, an alfa- and beta-adrenoreceptor antagonist with the diuretics, hydrochlorothiazide and furosemide) on the progression of CKD after 5/6 renal ablation (5/6 NX) in Ren-2 renin transgenic rats (TGR), a model of AngII-dependent hypertension. Normotensive transgene-negative Hannover Sprague-Dawley (HanSD) rats after 5/6 NX served as controls. 3. RAS-dependent and -independent antihypertensive therapies normalized BP and survival rate, and prevented the development of cardiac hypertrophy and glomerulosclerosis to the same degree in 5/6 NX HanSD rats and in 5/6 NX TGR. The present findings show that renoprotection, at least in rats after 5/6 NX, is predominantly BP-dependent. When equal lowering of BP was achieved, leading to normotension, cardio- and renoprotective effects were equivalent irrespective of the type of antihypertensive therapy. 4. These findings should be taken into consideration in attempts to develop new therapeutic approaches and strategies aimed to prevent the progression of CKD and to lower the incidence of ESRD.
dcterms:title
Similar renoprotection after renin-angiotensin-dependent and -independent antihypertensive therapy in 5/6-nephrectomized Ren-2 transgenic rats: are there blood pressure-independent effects? Similar renoprotection after renin-angiotensin-dependent and -independent antihypertensive therapy in 5/6-nephrectomized Ren-2 transgenic rats: are there blood pressure-independent effects?
skos:prefLabel
Similar renoprotection after renin-angiotensin-dependent and -independent antihypertensive therapy in 5/6-nephrectomized Ren-2 transgenic rats: are there blood pressure-independent effects? Similar renoprotection after renin-angiotensin-dependent and -independent antihypertensive therapy in 5/6-nephrectomized Ren-2 transgenic rats: are there blood pressure-independent effects?
skos:notation
RIV/00064173:_____/10:00002699!RIV13-MZ0-00064173
n3:aktivita
n10:V n10:Z n10:S n10:P
n3:aktivity
P(1M0510), P(GA305/07/0167), P(GC305/07/J004), P(GC305/08/J006), P(GP305/08/P053), P(KJB502030801), P(NS10499), P(NS10500), P(NS9699), P(NS9703), S, V, Z(MZ0IKEM2005)
n3:cisloPeriodika
12
n3:dodaniDat
n15:2013
n3:domaciTvurceVysledku
n8:8675007 n8:2489104
n3:druhVysledku
n18:J
n3:duvernostUdaju
n6:S
n3:entitaPredkladatele
n13:predkladatel
n3:idSjednocenehoVysledku
287319
n3:idVysledku
RIV/00064173:_____/10:00002699
n3:jazykVysledku
n16:eng
n3:klicovaSlova
r enoprotection; renin-angiotensin-aldosterone system; hypertension; glomerulosclerosis; end-organ damage; angiotensin-II receptor antagonist type 1; bangiotensin-converting enzyme inhibitor; alpha and beta adrenergic receptor antagonist
n3:klicoveSlovo
n4:bangiotensin-converting%20enzyme%20inhibitor n4:end-organ%20damage n4:hypertension n4:renin-angiotensin-aldosterone%20system n4:r%20enoprotection n4:angiotensin-II%20receptor%20antagonist%20type%201 n4:glomerulosclerosis n4:alpha%20and%20beta%20adrenergic%20receptor%20antagonist
n3:kodStatuVydavatele
US - Spojené státy americké
n3:kontrolniKodProRIV
[F987EFB30201]
n3:nazevZdroje
Clinical and Experimental Pharmacology and Physiology
n3:obor
n12:FA
n3:pocetDomacichTvurcuVysledku
2
n3:pocetTvurcuVysledku
18
n3:projekt
n5:NS10499 n5:NS10500 n5:GC305%2F08%2FJ006 n5:NS9703 n5:GA305%2F07%2F0167 n5:NS9699 n5:GP305%2F08%2FP053 n5:1M0510 n5:GC305%2F07%2FJ004 n5:KJB502030801
n3:rokUplatneniVysledku
n15:2010
n3:svazekPeriodika
37
n3:tvurceVysledku
Kujal, Petr Vernerová, Zdeňka
n3:wos
000284768900010
n3:zamer
n7:MZ0IKEM2005
s:issn
0305-1870
s:numberOfPages
11
n19:doi
10.1111/j.1440-1681.2010.05453.x